Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Bone mineral content and bone metabolism during physiological GH treatment in GH-deficient adults--an 18-month randomised, placebo-controlled, double blinded trial

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Distinguishing between hidden testes and anorchia: The role of endocrine evaluation in infancy and childhood

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Heritability of pubertal timing: detailed evaluation of specific milestones in healthy boys and girls

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Continuous decline in bone mineral density and deterioration of bone microarchitecture 7 years after Roux-en-Y gastric bypass surgery

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Hashimoto's thyroiditis as a risk factor for thyroid cancer

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Disease Control and Gender Predict the Socioeconomic Effects of Acromegaly: A Nationwide Cohort Study

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Ecological momentary assessments (EMAs) did not improve responsiveness of patient-reported outcomes on quality of life

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Is the alpha-galactosidase A variant p.Asp313Tyr (p.D313Y) pathogenic for Fabry disease? A systematic review

    Research output: Contribution to journalReviewResearchpeer-review

View graph of relations

OBJECTIVE: To evaluate the effect of physiological adult growth hormone (GH) replacement on bones.

DESIGN: Thirty-six prospective severely growth hormone-deficient (GHD) adults (22 females and 14 males) were randomised to either 18 months of GH (0.03 mU/kg/day) or placebo treatment.

METHODS: Bone mineral density and content (BMD, BMC) and body composition were evaluated by dual energy X-ray absorptiometry at baseline and after 6, 12 and 18 months. Serum concentrations of insulin-like growth factor-I (IGF-I), IGF binding protein 3, osteocalcin, carboxyterminal propeptide of type I collagen, carboxyterminal crosslink telopeptide of type I collagen, amino-terminal propeptide of type III procollagen and urine pyridinolin and deoxypyridinolin were determined.

RESULTS: IGF-I levels increased from 63.2 microg/l (+/-10.1) to 193.6 (+/- 25.8) microg/l (mean (+/-s.e.)) (P<0.001 compared with placebo). Markers of bone turnover increased significantly from 142% to 227% of baseline values (all P<0.001 compared with placebo). Body composition changes were an increase of lean body mass and a decrease of fat mass resulting in a reduction of percentage body fat of +/- 1.8 (+/- 3.8) in the GH-treated group vs an increase of 1.0 (+/-2.9)) in the placebo-treated group (P=0.002).

CONCLUSIONS: No significant difference in BMD or BMC between the GH and placebo groups was found after 18 months. At several sites the variances of changes from baseline were significantly greater in the GH than in the placebo group, indicating an impact of the treatment. From baseline to 6 months an insignificant reduction of total BMD was seen while an increase of BMD was found from 6 to 18 months in the GH group compared with the placebo group. This placebo-controlled trial confirmed the longer term open studies on the effect on bones in patients with GHD, with an initial overrepresentation of bone resorption followed by an increase in BMD which at 18 months had reached baseline level.

Original languageEnglish
JournalEuropean Journal of Endocrinology
Volume146
Issue number2
Pages (from-to)187-95
Number of pages9
ISSN0804-4643
DOIs
Publication statusPublished - Feb 2002

    Research areas

  • Adult, Amino Acids/urine, Body Composition, Bone Density, Bone Remodeling, Bone and Bones/metabolism, Collagen/blood, Collagen Type I, Double-Blind Method, Female, Human Growth Hormone/deficiency, Humans, Insulin-Like Growth Factor Binding Protein 3/blood, Insulin-Like Growth Factor I/analysis, Male, Middle Aged, Osteocalcin/blood, Peptide Fragments/blood, Peptides/blood, Placebos, Procollagen/blood, Prospective Studies, Protein Precursors/blood, Time Factors

ID: 59041101